Login / Signup

Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.

Nooraldin MerzaYusuf NawrasOmar SaabDushyant Singh DahiyaZohaib AhmedMeghana RanabothuSafa BoujemaaMona HassanAbdallah KobeissyKirthi Lilley
Published in: Gastroenterology research (2023)
ADA and VDZ are effective and safe in CD and UC patients. However, RCTs of a larger number of patients are still required for better assessing the safety profile of ADA and VDZ.
Keyphrases
  • end stage renal disease
  • ulcerative colitis
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • rheumatoid arthritis
  • early onset
  • patient reported
  • disease activity